ADC Post-Endocrine Therapy Misses Mark in Advanced Breast Cancer Trial

By News Health
1 hour Ago

(MedPage Today) — SAN ANTONIO — The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first treatment after endocrine therapy for metastatic hormone receptor-positive/HER2-negative breast cancer…

Source link : https://www.medpagetoday.com/meetingcoverage/sabcs/118963

Author :

Publish date : 2025-12-11 20:07:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

RFK Jr.'s Viral Pull-Ups; Docs Denounce ACIP's Hep B Vote; 'Don't Pee!'

FDA Proposes Allowing New Sunscreen Ingredient

FDA OKs First At-Home Brain Stim Device for Depression

Expand Labeling for Testosterone Replacement Therapy, FDA Panel Says

Incretin-Based Meds May Modestly Raise Biliary Risk in T2D

RFK Jr. Tops This Year's Shkreli Awards